PEDIATRICS Vol. 91 No. 4 April 1993, pp. 747-751
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butler, K. M.
Right arrow Articles by Venzon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butler, K. M.
Right arrow Articles by Venzon, D.

Pancreatitis in Human Immunodeficiency Virus-Infected Children Receiving Dideoxyinosine

Karina M. Butler MB, BCh, MRCPI1, Nancy Henry MD1, Robert N. Husson MD1, Brigitta U. Mueller MD1, Frank M. Balis MD1, Freda Jacobsen RN1, Linda L. Lewis MD1, Philip A. Pizzo MD1, and David Venzon PhD2

1 From the Pediatric Branch, National Cancer Institute, Bethesda, MD.
2 From the Biostatistics and Data Management Section, Clinical Oncology Program, National Cancer Institute, Bethesda, MD.

To define predictive or contributory risk factors for pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine (ddI), the authors evaluated 95 children, 3 months to 18 years of age, who had received ddI at 60 to 540 mg/m2 per day for a mean of 56 weeks. Pancreatitis developed in 7 patients (7%) but resolved in all upon withdrawal of ddI. Neither age, sex, nor CD4 count at study entry was predictive of pancreatitis, but pancreatitis appeared more likely to develop in hemophiliacs than in other patients (4 of 23 vs 3 of 72). Pancreatitis developed only in patients who received ddI at the highest dose levels (7 of 60 patients who received ddI at a dose ge 360 mg/m2 per day vs 0 of 35 patients who received <270 mg/m2 per day). Patients in whom pancreatitis developed had received a higher mean daily dose of ddI than patients with normal amylase and lipase levels throughout the study (348 mg/m2 vs 282 mg/m2), but no relationship with the cumulative dose or the duration of ddI therapy was observed. Although a statistically significant relationship between ddI plasma concentration (area under the curve) and pancreatitis was not conclusively demonstrated, as the number of patients in whom pancreatitis actually developed was small, such a relationship may have been obscured. The mean interval from initiation of ddI to onset of symptoms of pancreatitis (25 weeks) was significantly shorter than the average duration of ddI therapy (56 weeks), and, consequently, patients in whom pancreatitis developed had been exposed to a lower cumulative dose of ddI than those with normal amylase and lipase levels (64.5 g/m2 vs 119.06 g/m2). Although baseline amylase values did not correlate with the later development of pancreatitis, elevation of baseline aspartate aminotransferase and alanine aminotransferase levels was significantly associated with the later development of pancreatitis.

Key Words: pancreatitis • dideoxyinosine • human immunodeficiency virus • antiretroviral therapy

Submitted on July 20, 1992
Accepted on November 3, 1992




This article has been cited by other articles:


Home page
 J Trop PediatrHome page
I. Shah
Adverse Effects of Antiretroviral Therapy in HIV-1 Infected Children
J Trop Pediatr, August 1, 2006; 52(4): 244 - 248.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Antiretroviral Therapy and Medical Management of Pediatric HIV Infection
Pediatrics, October 1, 1998; 102(4): 1005 - 1062.
[Full Text]